Advertisement

Topics

Vizient, Inc. Applauds FDA’s Heightened Focus on Preventing Drug Shortages

10:51 EDT 13 Jul 2018 | Businesswire

Vizient, Inc.

Vizient, Inc. applauds the U.S. Food and Drug Administration (FDA) for forming a new drug shortages task force and advancing long-term solutions to prevent shortages.

Stable and reliable supply, along with cost and safety, are always top priorities for Vizient. In addition to regular communication and education to our health care members, for years we’ve worked to mitigate the impact of shortages and price spikes through innovative contracting strategies and alternative drug therapies, as well as by being actively involved in advocating for legislative language to encourage competition.

“Access to affordable drugs is one of the most critical challenges facing health care today,” says Dan Kistner, senior vice president, pharmacy solutions at Vizient. “For over a decade, drug shortages have plagued hospitals and become a routine obstacle around which providers have had to navigate. It is a natural extension of Vizient’s mission to work collaboratively with all stakeholders to find innovative solutions to prevent drug shortages.” Vizient is committed to working with the FDA and other stakeholders to improve the safety and reliability of the supply chain.

Vizient is the nation’s largest health care performance improvement company serving a diverse membership that includes academic medical centers, pediatric facilities, community hospitals, integrated health care delivery networks and non-acute health care providers.

About Vizient, Inc.

Vizient, Inc., the largest member-driven health care performance improvement company in the country, provides innovative data-driven solutions, expertise and collaborative opportunities that lead to improved patient outcomes and lower costs. Vizient’s diverse membership base includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume. The Vizient brand identity represents the integration of VHA Inc., University HealthSystem Consortium and Novation, which combined in 2015, as well as MedAssets’ Spend and Clinical Resource Management (SCM) segment, including Sg2, which was acquired in 2016. In 2018, Vizient again received a World’s Most Ethical Company designation from the Ethisphere Institute. Vizient’s headquarters are in Irving, Texas, with locations in Chicago and other cities across the United States. Please visit www.vizientinc.com as well as our newsroom, blog, Twitter, LinkedIn and YouTube pages for more information about the company.

Vizient, Inc.
Angie Boliver, 972-830-7961
angie.boliver@vizientinc.com

NEXT ARTICLE

More From BioPortfolio on "Vizient, Inc. Applauds FDA’s Heightened Focus on Preventing Drug Shortages"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...